132 related articles for article (PubMed ID: 10891474)
1. Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase.
Boultwood J; Peniket A; Watkins F; Shepherd P; McGale P; Richards S; Fidler C; Littlewood TJ; Wainscoat JS
Blood; 2000 Jul; 96(1):358-61. PubMed ID: 10891474
[TBL] [Abstract][Full Text] [Related]
2. Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia.
Boultwood J; Fidler C; Shepherd P; Watkins F; Snowball J; Haynes S; Kusec R; Gaiger A; Littlewood TJ; Peniket AJ; Wainscoat JS
Am J Hematol; 1999 May; 61(1):5-9. PubMed ID: 10331504
[TBL] [Abstract][Full Text] [Related]
3. The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myeloid leukemia.
Iwama H; Ohyashiki K; Ohyashiki JH; Hayashi S; Kawakubo K; Shay JW; Toyama K
Cancer; 1997 Apr; 79(8):1552-60. PubMed ID: 9118038
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry.
Brümmendorf TH; Holyoake TL; Rufer N; Barnett MJ; Schulzer M; Eaves CJ; Eaves AC; Lansdorp PM
Blood; 2000 Mar; 95(6):1883-90. PubMed ID: 10706851
[TBL] [Abstract][Full Text] [Related]
5. The dual expression of minor and major bcr/abl chimeric mRNA in blast crisis of chronic myelogenous leukemia.
Tanaka M; Yamazaki Y; Hattori M; Tsushita K; Utsumi M; Yoshida S
Leuk Res; 1996 Jul; 20(7):575-80. PubMed ID: 8795691
[TBL] [Abstract][Full Text] [Related]
6. Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia.
Drummond M; Lennard A; Brûmmendorf T; Holyoake T
Leuk Lymphoma; 2004 Sep; 45(9):1775-81. PubMed ID: 15223635
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Hochhaus A; Heinze B
Blood; 1994 Dec; 84(12):4064-77. PubMed ID: 7994025
[TBL] [Abstract][Full Text] [Related]
9. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
10. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
11. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
Haaß W; Kleiner H; Weiß C; Haferlach C; Schlegelberger B; Müller MC; Hehlmann R; Hofmann WK; Fabarius A; Seifarth W; ;
PLoS One; 2015; 10(6):e0129648. PubMed ID: 26087013
[TBL] [Abstract][Full Text] [Related]
12. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
13. Clonally unrelated BCR-ABL-negative acute myeloblastic leukemia masquerading as blast crisis after busulphan and interferon therapy for BCR-ABL-positive chronic myeloid leukemia.
Manley R; Cochrane J; McDonald M; Rigby S; Moore A; Kirk A; Clarke S; Crossen PE; Morris CM; Patton WN
Leukemia; 1999 Jan; 13(1):126-9. PubMed ID: 10049047
[TBL] [Abstract][Full Text] [Related]
14. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
[TBL] [Abstract][Full Text] [Related]
15. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
16. Preliminary research on the p53 gene rearrangements in the evolution of chronic myelogenous leukemia to blast crisis.
Chen JC; Liu SM; Fei HB; Gong WL
J Tongji Med Univ; 1994; 14(4):204-8. PubMed ID: 7760428
[TBL] [Abstract][Full Text] [Related]
17. Extramedullary blast crisis in a patient with chronic myelogenous leukemia in complete cytogenetic and molecular remission on interferon-alpha therapy.
Beedassy A; Topolsky D; Styler M; Crilley P
Leuk Res; 2000 Aug; 24(8):733-5. PubMed ID: 10936425
[TBL] [Abstract][Full Text] [Related]
18. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.
Higano CS; Chielens D; Raskind W; Bryant E; Flowers ME; Radich J; Clift R; Appelbaum F
Blood; 1997 Oct; 90(7):2549-54. PubMed ID: 9326220
[TBL] [Abstract][Full Text] [Related]
19. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
Okabe M
Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
[TBL] [Abstract][Full Text] [Related]
20. Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders.
Brümmendorf TH; Rufer N; Holyoake TL; Maciejewski J; Barnett MJ; Eaves CJ; Eaves AC; Young N; Lansdorp PM
Ann N Y Acad Sci; 2001 Jun; 938():293-303; discussion 303-4. PubMed ID: 11458518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
